|
February 2026
|
Laboratory Business Insights
Billing, Operational, and Staffing News for Laboratories
Presented by ADSRCM and ADS, Leading Providers of Outsourced Billing Service/Staffing or In-Laboratory Revenue Cycle Management Systems
.png?width=1200&height=1500&name=National%20Sales%20Manager%2c%20Laboratory%20(2).png)
Laboratory Revenue Stability in a Post-PAMA Reset Environment
A Message from Jim:
Clinical laboratories avoided immediate Medicare cuts thismonth — but that does not mean the pressure is gone.
The Consolidated Appropriations Act of 2026 delayedPAMA-related payment reductions until January 1, 2027. Labs were facingreimbursement cuts of up to 15% on nearly 800 tests. That pause providestemporary relief.
It also resets the clock.
Between May 1 and July 31, 2026, applicablelaboratories must report private payor data from January 1 – June 30, 2025.That data will determine your Medicare rates beginning in 2027.
For lab directors, owners, and CFOs, this is not simply acompliance deadline. It is a revenue cycle inflection point.
What I am watching most closely is revenue defensibility.When PAMA reporting, denial acceleration, Medicare Advantage scrutiny, and DOJenforcement converge, laboratory margin stability becomes a front-endoperational discipline — not a back-end recovery exercise.
The labs preparing now will protect reimbursement long-term.Those that wait risk locking in lower rates for years.
PAMA 2027 Shift: What It Means for Laboratory Billing
Here is what changed:
• Medicare lab cuts delayed until January 1, 2027
• New reporting window: May 1 – July 31, 2026
• Data baseline: Jan 1 – June 30, 2025 private payor payments
• 15% annual reduction cap extended through 2027–2029
More current data is a positive development — but only ifyour billing data is clean.
If payer mapping is incorrect, if “miscellaneous” codes wereused, if zero-dollar claims are mistakenly included, or if final paid claimsare misclassified, your reported weighted median could permanently reduceMedicare reimbursement.
2026 is a revenue integrityyear for laboratories.
Denial Acceleration and Cash Flow Pressure
While the PAMA delay grabbed headlines, denial trends arealready tightening margins.
Early 2026 system data shows:
• Denial rates up 220–340 basis points year-over-year
• Median Days in A/R increasing from 47.8 to 52.1
• Appeals backlogs expanding 15–22%
For laboratories heavily exposed to Medicare Advantage andcommercial managed care, this elongates revenue recognition and increasesworking capital strain.
At the same time, revenue cycle staffing vacancy ratesremain elevated at 14–18% across healthcare. Many labs are operatinglean billing teams just as payer algorithms become more aggressive.
Denial inflation is no longer episodic. It is algorithmic.
If your denial rate rises even 2–3%, that erosion compoundsquickly — especially heading into a PAMA recalibration year.
Medicare Advantage Oversight and Downstream Impact
CMS continues expanding Risk Adjustment Data Validation(RADV) methodology for 2026, with extrapolation authority projected to drive $4.2B–$7.1Bin multi-year plan recoveries.
While RADV targets plan payments, downstream providerscrutiny increases in parallel.
For laboratories, that translates into:
• More medical necessity documentation requests
• Increased chart review tied to risk-adjusted diagnoses
• Heightened defensibility requirements for specialty panels
When extrapolation sensitivity increases, diagnosticservices are not immune.
DOJ Enforcement: Billing Is Now an Enterprise Risk
Federal enforcement visibility is increasing as well.
Recent DOJ actions tied to telehealth and diagnostic billinghave totaled approximately $180M in alleged fraud exposure in early 2026alone.
Enforcement focus areas impacting labs include:
Medical Necessity & Panel Utilization
High-reimbursement tests — particularly genetic panels — remain under scrutinywhen documentation is insufficient.
Referral & Marketing Relationships
Third-party marketers and telehealth networks continue triggering Anti-Kickbackinvestigations.
Data Analytics-Driven Investigations
CMS and DOJ use advanced analytics to identify:
• High utilization of specific test codes
• Geographic anomalies
• Outlier provider ordering patterns
• Frequency and unbundling trends
If regulators can see billing anomalies, laboratoryleadership must see them first.
The central question for lab executives is no longer:
“Are we getting paid?”
It is:
“Would this revenue withstand federal review?”
Compliance and revenue cyclemanagement are now structurally connected.
Operational Readiness for 2026 Reporting
Between now and May 2026, laboratory leaders should focus onthree priorities:
1. Data Integrity
• Audit 2025 private payor payments
• Confirm final paid claims within the reporting window
• Validate HCPCS/CPT mapping accuracy
• Remove miscoded or bundled claims
2. Revenue Cycle Modernization
• Strengthen eligibility and medical necessity validation
• Reduce first-pass denial rates
• Model potential 2027 reimbursement impact by test category
• Review private payor contracts older than 18 months
3. Documentation Defensibility
• Ensure complete physician order capture
• Align coding with clinical documentation
• Monitor panel utilization trends
• Build audit trails aligned with regulator expectations
The laboratories that integrate billing accuracy, payerstrategy, compliance oversight, and reporting preparation into a unifiedframework will stabilize margin — even as external pressures intensify.
Structural Exposure: Q2–Q3 2026 Outlook
As we move further into 2026, expect:
• Faster denial decision cycles
• Higher documentation thresholds
• Increased Medicare Advantage review intensity
• Greater pre-payment review for specialty diagnostics
• Heightened audit sensitivity tied to telehealth and high-cost testing
The competitive advantage will not be scale alone.
It will be clarity and control inside your revenue cycle architecture.
How ADS Supports Laboratory Revenue Integrity
In this environment, a billing partner must function as partof your risk control framework — not simply a claims processor.
ADS helps laboratories:
• Clean and validate private payor data ahead of PAMAreporting
• Reduce denial rates through automated front-end validation
• Align CPT/HCPCS coding with documentation
• Identify utilization outliers through advanced reporting
• Strengthen audit readiness
• Improve cash flow and reduce revenue leakage
The objective is simple:
Protect reimbursement today.
Defend revenue tomorrow.
Prepare Your Laboratory for PAMA 2026 Reporting and 2027Reimbursement
https://www.adsc.com/laboratory-billing-software
Thanks for choosing ADS. Let’s keep building what works.
The ADSRCM Client Success Team - Laboratory Division
www.adsc.com/laboratory-billing-software
We hope you enjoyed the read.
Contact us about outsourced billing/staffing services (ADSRCM), or about MedicsPremier as an in-laboratory platform from ADS. We’ll help drive revenue and productivity in ways that work best for you. 800-899-4237, Ext. 2264 or info@adsc.com.
<<< >>>
Next Up:
March, with new articles and items of interest for laboratories!
We strive to provide our newsletters with news of the current month, not the previous month.
We greatly appreciate feedback or comments on our newsletters/content. Please opine by emailing christina.r@adsc.com or by calling 800-899-4237, Ext. 2264. We’d love to hear from you!
Disclaimer: Articles and content about governmental information, such as CMS, Medicare, and Medicaid, are presented according to our best understanding. Please visit www.cms.gov if clarifications are needed. We are not responsible for typographical errors or changes that may have occurred after this newsletter was produced. We don’t endorse any companies or organizations mentioned in our newsletters; you are encouraged to do research and due diligence on any that might interest you.
Keep up with the latest laboratory billing trends, insights, and industry news
Medical Billing / RCM | Laboratory
Billing Laboratory Tests Without LCDs: How Labs Can Stay Profitable Despite Coverage Gaps
By Jim O'Neill
on February 18th, 2026
Medical Billing / RCM | Laboratory
What’s Driving Revenue Leakage and What Practices Can Do About It
The Big Picture in 2026 In 2026, revenue leakage is no longer a back office inconvenience. It has ...
By Christina Rosario
on February 12th, 2026
Medical Billing / RCM | Laboratory
DOJ Enforcement of Clinical Laboratories: What Lab CFOs and Compliance Managers Need to Know Now
For clinical laboratories, compliance risk is no longer confined to the legal department. It is now ...
By Jim O'Neill
on February 11th, 2026